Related Experiment Videos
[Renal failure during treatment with Ambisome]
C Arvieux1, V Noyon, C Michelet
1Clinique des Maladies infectieuses et Réanimation médicale, CHRU Pontchaillou, Rennes. Cedric.Arvieux@univ-rennes1.fr
Presse Medicale (Paris, France : 1983)
|November 10, 2000
Summary
Liposome amphotericin B-deoxycholate (AmBisome) can cause renal failure in immunocompromised patients with candidosis. This risk of worsening kidney function must be considered, even when treating patients with existing renal impairment.
Area of Science:
- Pharmacology
- Nephrology
- Mycology
Background:
- Liposomal amphotericin B-deoxycholate (AmBisome) is used for fungal infections.
- Renal function is typically preserved with AmBisome, but risks exist.
Observation:
- Two immunocompromised patients with refractory oral/esophageal candidosis were treated with AmBisome.
- One patient developed moderate renal impairment; the second experienced worsening renal failure.
Findings:
- AmBisome treatment led to significant renal impairment in both patients.
- The second patient's renal function deteriorated severely after switching to AmBisome.
Implications:
- Clinicians must carefully weigh the benefits against the risk of nephrotoxicity with AmBisome.
- Patient monitoring for renal function is crucial during AmBisome therapy, especially in those with pre-existing kidney issues.